Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Is Conceptus, Inc. (CPTS) Going to Burn These Hedge Funds?

Page 1 of 2

Is Conceptus, Inc. (NASDAQ:CPTS) worth your attention right now? Investors who are in the know are buying. The number of long hedge fund bets moved up by 1 lately.

To the average investor, there are plenty of gauges investors can use to watch publicly traded companies. A couple of the most under-the-radar are hedge fund and insider trading activity. At Insider Monkey, our studies have shown that, historically, those who follow the best picks of the best money managers can trounce the broader indices by a superb margin (see just how much).


Equally as important, optimistic insider trading sentiment is a second way to break down the world of equities. Obviously, there are plenty of reasons for a bullish insider to get rid of shares of his or her company, but only one, very clear reason why they would behave bullishly. Various academic studies have demonstrated the useful potential of this tactic if shareholders understand what to do (learn more here).

Now, let’s take a gander at the key action encompassing Conceptus, Inc. (NASDAQ:CPTS).

How have hedgies been trading Conceptus, Inc. (NASDAQ:CPTS)?

At the end of the first quarter, a total of 13 of the hedge funds we track were long in this stock, a change of 8% from one quarter earlier. With the smart money’s capital changing hands, there exists an “upper tier” of key hedge fund managers who were boosting their holdings meaningfully.

According to our comprehensive database, Redmile Group, managed by Jeremy Green, holds the largest position in Conceptus, Inc. (NASDAQ:CPTS). Redmile Group has a $14 million position in the stock, comprising 2.6% of its 13F portfolio. On Redmile Group’s heels is William Leland Edwards of Palo Alto Investors, with a $10.9 million position; 1.3% of its 13F portfolio is allocated to the stock. Other hedgies that are bullish include Joseph Edelman’s Perceptive Advisors, Peter S. Park’s Park West Asset Management and Jim Simons’s Renaissance Technologies.

As aggregate interest increased, some big names have jumped into Conceptus, Inc. (NASDAQ:CPTS) headfirst. Catapult Capital Management, managed by Israel Englander, established the biggest position in Conceptus, Inc. (NASDAQ:CPTS). Catapult Capital Management had 2.8 million invested in the company at the end of the quarter. Israel Englander’s Millennium Management also initiated a $2.1 million position during the quarter. The following funds were also among the new CPTS investors: David Moradi’s Anthion Management and Donald Chiboucis’s Columbus Circle Investors.

What do corporate executives and insiders think about Conceptus, Inc. (NASDAQ:CPTS)?

Insider buying is best served when the company we’re looking at has seen transactions within the past six months. Over the latest 180-day time frame, Conceptus, Inc. (NASDAQ:CPTS) has seen zero unique insiders buying, and 4 insider sales (see the details of insider trades here).

Let’s also examine hedge fund and insider activity in other stocks similar to Conceptus, Inc. (NASDAQ:CPTS). These stocks are Endologix, Inc. (NASDAQ:ELGX), Luminex Corporation (NASDAQ:LMNX), ICU Medical, Incorporated (NASDAQ:ICUI), Cantel Medical Corp. (NYSE:CMN), and Tornier N.V. (NASDAQ:TRNX). This group of stocks belong to the medical instruments & supplies industry and their market caps are closest to CPTS’s market cap.

Page 1 of 2

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!